Method for preparing chroman compounds

Abstract

This application describes a method for preparing substituted chroman compounds without the use of pyrophoric reagents, making scale-up economically feasible. A synthetic route that does not require a column chromatographic purification step is also described. In particular, the present invention relates to the synthesis of calcium-sensing receptor (CaSR) modulators, 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid and pharmaceutically acceptable salts thereof.

Description

[Technical Field]

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This PCT application claims priority to Indian Provisional Patent Application No. 201921047127, filed on November 19, 2019, the contents of which are incorporated herein by reference in their entirety.

[0002] All references and works cited in this disclosure, including but not limited to patents, patent applications, and non-patent references, are hereby incorporated by reference in their entirety.

[0003] The present disclosure relates to methods for preparing substituted chroman compounds. More specifically, an efficient and safe synthesis of the calcium-sensing receptor (CaSR) modulator 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid, its intermediates, and its pharmaceutically acceptable salts is described. An efficient purification method for 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid, its intermediates, and its pharmaceutically acceptable salts is also described, making it economically feasible to scale up the production of these compounds. The process described herein is carried out without the use of pyrophoric reagents and without a column chromatographic purification step. The present invention also relates to intermediates used in the synthesis. In particular, the present invention relates to the synthesis of the calcium-sensing receptor (CaSR) modulator 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid, its intermediates, and its pharmaceutically acceptable salts. [Background technology]

[0004] The following includes information that may be useful in understanding the present invention. No admission is made that any information, publication, or document referenced herein, expressly or implicitly, is prior art or essential to the invention described or claimed. All publications and patents mentioned herein are incorporated herein by reference in their entirety.

[0005] The calcium-sensing receptor is a class C G protein-coupled receptor (GPCR). It plays a major role in maintaining physiological serum ionized calcium (Ca2+) concentrations by controlling circulating levels of parathyroid hormone. Extracellular Ca2+ ([Ca 2+ ] o ) is the major physiological ligand for CaSR.

[0006] Small molecules that are positive allosteric modulators of GPCRs, called calcimimetics, modulate and improve the receptor's sensitivity to the pre-existing extracellular ionized calcium environment, thereby reducing PTH secretion. GPCR modulation has been explored as a potential treatment for hyperparathyroidism and other diseases associated with reduced CaSR signaling. Cinacalcet was the first CaSR modulator to be approved by the U.S. Food and Drug Administration (FDA). Other molecules capable of modulating the CaSR are also known, as described in WO 2013 / 124828.

[0007] WO 2013 / 124828 discloses a series of substituted chroman compounds for the modulation of CaSR. One specific compound disclosed therein is 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid hydrochloride. The application also describes a general method for the synthesis of these substituted chroman compounds. Disadvantages of the methods described therein include the use of pyrophoric reagents (which are dangerous and therefore not feasible for large-scale use) and the use of purification techniques such as flash chromatography and expensive chiral chromatography to separate the compounds. The synthesis also involves harsh hydrogenation reaction conditions, which lead to the formation of undesired impurities. [Prior art documents] [Patent documents]

[0008] [Patent Document 1] WO2013 / 124828 [Non-patent literature]

[0009] [Non-Patent Document 1] "Advanced Organic Chemistry", 4th ed., March, Jerry, John Wiley & Sons, New York, 1992 [Non-patent document 2] Fieser and Fieser's Reagents for Organic Synthesis, volumes 1-17 (John Wiley and Sons, 1991) [Non-patent document 3] Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplements (Elsevier Science Publishers, 1989) [Non-patent document 4] Organic Reactions, vols. 1-40 (John Wiley and Sons, 1991) [Non-Patent Document 5] March's Advanced Organic Chemistry, (John Wiley and Sons, 4th edition) [Non-patent document 6] Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989) [Non-Patent Document 7] T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Chemistry," John Wiley and Sons, 1999 Summary of the Invention [Problem to be solved by the invention]

[0010] In light of the above, there is a need for a more efficient method for the preparation of 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid hydrochloride that is not only more economical but also uses less hazardous reagents at the same time.

[0011] The invention disclosed herein overcomes such limitations, allowing the synthesis of 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid and its pharmaceutically acceptable salts, as well as intermediates, to be prepared on an industrial scale with high purity without the use of complex and lengthy purification procedures.

[0012] The invention described and claimed herein has many features and aspects, including but not limited to those described or illustrated or referenced in this Summary of the Invention. It is not intended to be comprehensive, and the invention described and claimed herein is not limited to or by the features or embodiments identified in this Summary of the Invention, which is included for illustrative purposes only and not for limiting purposes. [Means for solving the problem]

[0013] In some aspects, the present disclosure provides a synthetic route to 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid and pharmaceutically acceptable salts thereof, and intermediates, in a synthesis, which can be carried out on an industrial scale without the use of complex and time-consuming purification procedures and with high purity, with less than about 1.0% of 2-methyl-5-((2R,4R)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman The present invention provides a synthetic route by which 2-methyl-5-((2R,4R)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid hydrochloride (Compound-B) can be prepared with less than about 0.5% of 2-methyl-5-((2R,4R)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid hydrochloride impurity, more particularly with less than about 0.2% of 2-methyl-5-((2R,4R)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid hydrochloride impurity.

[0014] The processes and methods disclosed herein are cost-effective and use mild, easy-to-handle reagents, and are therefore advantageous for preparing compounds on an industrial scale. Furthermore, these processes and methods do not use complicated or lengthy purification procedures, but can synthesize high quality and purity compounds with less than about 1.0% of 2-methyl-5-((2R,4R)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid hydrochloride (Compound-B) impurity, particularly less than about 0.5% of 2-methyl-5-((2R,4R)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid hydrochloride impurity, more particularly less than about 0.2% of 2-methyl-5-((2R,4R)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid hydrochloride impurity.

[0015] In some aspects, the present invention advantageously provides methods for preparing 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid and pharmaceutically acceptable salts thereof.

[0016] In some embodiments, the present invention provides a method for preparing 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid (Compound-4).

[0017] In some embodiments, the present invention provides a process for preparing 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid hydrochloride (Compound-A).

[0018] In some embodiments, the present invention provides a method for preparing 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid hydrochloride without using any chromatographic steps for isolation / purification.

[0019] In some embodiments, the present invention provides a compound having less than about 1.0% of 2-methyl-5-((2R,4R)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid hydrochloride (Compound-B) impurity, particularly less than about 0.5% of 2-methyl-5-((2R,4R)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid Provided is a process for preparing 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid hydrochloride (Compound-A) having impurities, more particularly less than about 0.2% of the 2-methyl-5-((2R,4R)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid impurity.

[0020] [ka]

[0021] In some embodiments, the present invention provides a compound having less than about 1.0% of the 2-methyl-5-((2R,4R)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid hydrochloride (Compound-B) impurity, particularly less than about 0.5% of the 2-methyl-5-((2R,4R)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid impurity, more particularly and a process for preparing 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid hydrochloride (Compound-A) having less than about 0.2% of the 2-methyl-5-((2R,4R)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid impurity, wherein a crystallization procedure is used.

[0022] In some embodiments, the present invention provides a method for preparing 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid hydrochloride (Compound-A) starting from methyl 5-((R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-2H-chromen-4-yl)-2-methylbenzoate (Compound-1), comprising: a) reducing methyl 5-((R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-2H-chromen-4-yl)-2-methylbenzoate (Compound-1) using Pd / C and ammonium formate to obtain methyl 5-((2R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)-2-methylbenzoate (Compound-2);

[0023] [ka]

[0024] b) Boc deprotection of Compound-2 to obtain the corresponding aminomethyl 2-methyl-5-((2R)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoate hydrochloride (Compound-3)

[0025] [ka]

[0026] c) hydrolysis of the ester group of Compound-3 and isolation of the pure diastereoisomer by using recrystallization techniques to obtain 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid (Compound-4).

[0027] [ka]

[0028] and d) converting compound-4 to its hydrochloride salt, 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid hydrochloride

[0029] [ka]

[0030] A manufacturing method according to the steps of:

[0031] In some embodiments, compound-4 can be converted to a hydrobromide, hydroiodide, sulfate, nitrate, tosylate, or carbonate salt.

[0032] In some embodiments, the double bond of compound-1 is reduced to give compound-2. The reaction is carried out using ammonium formate (10 eq) and 5% Pd / C (50% wet and 10% w / w supported), 10% Pd / C, or 2% Pd / C in an ethyl acetate-methanol solvent system with heating at about 33°C to about 34°C. This transfer hydrogenation can be carried out in aqueous or organic solvents using a formate, e.g., ammonium formate or sodium formate, as the hydrogen source with a Pd-C catalyst. The inventors have designed a synthetic route to compound-A that includes formate as the hydrogen source, allowing for safe scale-up without the need for external hydrogen gas as a reducing agent. Avoiding the use of external hydrogen gas also reduces infrastructure costs for scale-up, which would otherwise require minimizing hazards associated with hydrogen gas explosions. Therefore, the inventors have recognized the significant benefits of the synthetic route described herein, which does not require the use of external hydrogen gas.

[0033] In some embodiments, the reduction of the double bond of Compound-1 to give Compound-2 is carried out at a temperature between about 10° C. and about 50° C., more preferably between about 30° C. and about 33° C. This reaction can be carried out in any suitable solvent, including halogenated hydrocarbons, C6-C6 14 The reaction solvent may include or exclude aromatic hydrocarbons, C1-C5 alcohols, C2-C7 esters, C4-C7 ethers, C1-C5 carboxylic acids, water, or suitable mixtures thereof. In some embodiments, the reaction solvent may include or exclude water, methanol, isopropyl alcohol, dichloromethane, toluene, ethyl acetate, diethyl ether, and combinations thereof.

[0034] In some embodiments, the Boc deprotection reaction of compound-2 is carried out using hydrochloric acid in methanol at reflux at about 63° C. In some embodiments, the concentration of hydrochloric acid is 6N aqueous HCl. In some embodiments, Boc deprotection can occur using AlCl, trifluoroacetic acid in dichloromethane, or using a sequential treatment with trimethylsilyl iodide followed by methanol. In some embodiments, Boc deprotection can be carried out in the presence of a cation scavenger. The cation scavenger may include or exclude anisole or thioanisole.

[0035] In some embodiments, hydrolysis of Compound-3 is carried out using sodium hydroxide in a methanol-tetrahydrofuran solvent system with heating at about 55° C. In some embodiments, hydrolysis can occur using any hydroxide base (e.g., lithium hydroxide, potassium hydroxide, cesium hydroxide), or lithium chloride, followed by aqueous reaction with the resulting carboxylic acid lithium salt to the carboxylic acid.

[0036] In some embodiments, isolation of diastereoisomerically pure Compound-4 from the crude hydrolysis product of Compound-3 is achieved by recrystallization techniques using a solvent mixture of a protic polar solvent and an aprotic polar solvent. In some embodiments, the protic polar solvent may include or exclude ethanol, methanol, isopropanol, or a combination thereof. In some embodiments, the aprotic polar solvent may include or exclude dichloromethane, dimethylformamide, tetrahydrofuran, or a combination thereof. In some embodiments, the recrystallization method involves heating the reaction mixture in a solvent, e.g., in a solvent-nonsolvent mixture, to above 55°C and allowing the solution to slowly cool to room temperature or below, thereby preferentially crystallizing seed crystals of the desired compound (e.g., Compound 4) while the undesired compound (e.g., Compound 3) remains substantially dissolved. Capture of the isolated, substantially pure product (e.g., Compound 4), optionally followed by washing with a pre-cooled solvent-nonsolvent solution, affords substantially purified Compound 4, free or substantially free of impurities.

[0037] In some embodiments, isolation of diastereomerically pure Compound-4 from the crude hydrolysis product of Compound-3 is accomplished by recrystallization techniques using an ethanol:dichloromethane solvent mixture. In some embodiments, the ratio of ethanol to dichloromethane (v / v) can range from 1:5 to 5:1.

[0038] In some embodiments, the conversion of Compound-4 to Compound-A is carried out using acid neutralization with hydrochloric acid. In some embodiments, the hydrochloric acid is a 2N aqueous HCl solution.

[0039] In some embodiments, the present invention provides a method for preparing methyl 5-((R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-2H-chromen-4-yl)-2-methylbenzoate (Compound-1), comprising the following steps: a) reduction of the amide group of (R)-N-((R)-1-(naphthalen-1-yl)ethyl)chroman-2-carboxamide (Compound-5) using sodium bis(2-methoxyethoxy)aluminum hydride in toluene (such as sodium bis(2-methoxyethoxy)aluminum hydride known under the tradename Vitride™), followed by hydrochloride salt formation using concentrated HCl to give (R)-N-((R)-chroman-2-ylmethyl)-1-(naphthalen-1-yl)ethanamine hydrochloride (Compound-6);

[0040] [ka]

[0041] b) protecting the free amino group of Compound-6 using Boc anhydride (di-tert-butyl dicarbonate) and tripotassium phosphate to give tert-butyl ((R)-chroman-2-ylmethyl)((R)-1-(naphthalen-1-yl)ethyl)carbamate (Compound-7)

[0042] [ka]

[0043] c) oxidation of Compound-7 using KMnO4 and MgSO4 to obtain tert-butyl ((R)-1-(naphthalen-1-yl)ethyl)(((R)-4-oxochroman-2-yl)methyl)carbamate (Compound-8)

[0044] [ka]

[0045] d) reacting Compound-8 with a triflating agent (which may or may not include N-phenyl-bis(trifluoromethanesulfonimide), trifluoromethanesulfonic anhydride, trifluoromethanesulfonyl chloride, 4-nitrophenyl trifluoromethanesulfonate, or 1-(trifluoromethanesulfonyl)imidazole) to obtain (R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-2H-chromen-4-yl trifluoromethanesulfonate (Compound-9).

[0046] [ka]

[0047] and e) coupling Compound-9 with methyl 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate in the presence of a palladium catalyst (which may or may not include palladium-tetrakis(triphenylphosphine), palladium(II) bis(triphenylphosphine) dichloride, palladium(0) bis(dibenzylideneacetone), palladium(II) bis(triphenylphosphine) diacetate, or [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II)) to provide methyl-5-((R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-2H-chromen-4-yl)-2-methylbenzoate (Compound-1).

[0048] [ka]

[0049] A method of preparation is provided, comprising:

[0050] In some embodiments, reduction of Compound-5 is carried out using sodium bis(2-methoxyethoxy)aluminum hydride (such as sodium bis(2-methoxyethoxy)aluminum hydride, known under the trade name Vitride™) in toluene (70% w / w). Sodium bis(2-methoxyethoxy)aluminum hydride is a non-pyrophoric reducing agent.

[0051] The drawings form part of the present specification and are included to further demonstrate certain aspects of the embodiments described herein, which may be better understood by reference to one or more of the following drawings in combination with the detailed description. [Brief explanation of the drawings]

[0052] [Figure 1] 1 is a powder X-ray diffraction profile (x-axis is 2-theta coordinate) of Compound-A made by a representative synthetic route of the present disclosure. [Figure 2] 1 is an example HPLC chromatogram for Compound-A and Compound-B made by a representative synthetic route of the present disclosure. A list of corresponding peaks is provided below in Table 2. [Figure 3] 1 is an example HPLC chromatogram for Compound-A and Compound-B made by a representative synthetic route of the present disclosure. A list of corresponding peaks is provided below in Table 3. DETAILED DESCRIPTION OF THE INVENTION

[0053] It is to be understood that the processes, methods, and / or systems herein are not limited to particular synthetic processes, methods or systems, specific components, or particular compositions. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting.

[0054] definition General terms used in the process may be defined as follows, however the defined meanings should not be construed as limiting the scope of the terms themselves.

[0055] As used herein, the recitation of a numerical range for a variable conveys that the invention may be practiced with the variable equal to any of the values ​​within that range. Thus, for a variable that is discrete in nature, the variable can be equal to any integer value within that numerical range, inclusive of the endpoints of the range. Similarly, for a variable that is continuous in nature, the variable can be equal to any real value within that numerical range, inclusive of the endpoints of the range. As an example, a variable described as having a value between 0 and 2 can be 0, 1, or 2 for a variable that is discrete in nature, or 0.0, 0.1, 0.01, 0.001, or any other real value for a variable that is continuous in nature.

[0056] As used herein, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Ranges may be stated herein as from "about" one particular value, and / or to "about" another particular value. When such a range is stated, another embodiment includes from the one particular value and / or to the other particular value. Similarly, when values ​​are stated as approximations, by use of the antecedent "about," it will be understood that the particular value forms another embodiment. It will also be understood that the endpoints of each of the ranges have meaning both in relation to the other endpoint, and independently of the other endpoint.

[0057] As used herein, the term "about" modifies the numerical value to which it refers and expresses such value as a variable within a margin of error. Unless a specific margin of error, such as a standard deviation relative to an average value, is given, the term "about" means plus or minus 10% of the numerical value of the number with which it is used. For example, "about 50%" means within a range of 45% to 55%.

[0058] The term "alkyl," as used herein, refers to a branched or unbranched hydrocarbon group, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, pentyl, hexyl, heptyl, octyl, nonyl, decyl, and dodecyl. Alkyl groups can also be substituted or unsubstituted. Unless otherwise specified, the term "alkyl" contemplates both substituted and unsubstituted alkyl groups. Alkyl groups can be optionally substituted with one or more groups, including, but not limited to, alkoxy, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, aldehyde, amino, carboxylic acid, ester, ether, halide, hydroxy, ketone, nitro, silyl, sulfo-oxo, or thiol.

[0059] As used herein, the term "diastereomers" refers to stereoisomers that are not mirror images of one another. The term "isomers" refers to compounds that have identical molecular formulae but differ in the nature or sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are called "stereoisomers." Diastereoisomers that are non-superimposable mirror images are called "enantiomers" or sometimes "optical isomers." A carbon atom bonded to four non-identical substituents is called a "chiral center." A compound with one chiral center, having two enantiomeric forms of opposite chirality, is called a "racemic mixture." A compound with more than one chiral center has 2n-1 enantiomeric pairs, where n is the number of chiral centers. A compound with more than one chiral center can exist either as an individual diastereomer or as a mixture of diastereomers, called a "diastereomeric mixture." When one chiral center is present, a stereoisomer can be characterized by the absolute configuration of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. Enantiomers are characterized by the absolute configuration of their chiral centers and are described by the Cahn-Ingold-Prelog R- and S-sequencing rules. Stereochemical nomenclature conventions, methods for determining stereochemistry, and separation of stereoisomers are well known in the art (see, e.g., "Advanced Organic Chemistry," 4th ed., March, Jerry, John Wiley & Sons, Inc., New York, 1992).

[0060] As used herein, the term "pharmaceutically acceptable" refers to those that are generally safe, non-toxic, biologically or otherwise useful in preparing pharmaceutical compositions, and includes those that are acceptable for veterinary use and for human medicine.

[0061] As used herein, the term "pharmaceutically acceptable salt" refers to a salt of a compound of the present disclosure that is pharmaceutically acceptable, as defined above, and possesses the desired pharmacological activity. Such salts include acid addition salts formed with inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid; or with organic acids, such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, O-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methylsulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzoic ... These include acid addition salts formed with benzenesulfonic acid, p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]oct-2-ene-1-carboxylic acid, glucoheptonic acid, 4,4'-methylenebis(3-hydroxy-2-ene-1-carboxylic acid), 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, lauryl sulfonic acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, and muconic acid.

[0062] Pharmaceutically acceptable salts also include base addition salts that can be formed when the acidic protons present can react with inorganic or organic bases. Acceptable inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide, and calcium hydroxide. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.

[0063] As used herein, the term "pyrophoric" refers to a material that spontaneously ignites in the presence of air or within 5 minutes after contact with air. Common reducing agents are often pyrophoric and include LiAlH, NaH, diisobutylaluminum hydride, metal hydrides, tributyltin, borane complexes (e.g., BH-THF), and hydrogen gas (with a catalyst), among others. As used herein, a "non-pyrophoric" agent refers to a material that does not spontaneously ignite in the presence of air or within 5 minutes after contact with air.

[0064] As used herein, the term "suitable crystallization conditions" refers to conditions selected to crystallize the desired compound from a mixture of compounds, preferably compound 4, from a mixture of compounds 3 and 4. Examples of solvent systems that can be used to carry out this crystallization include, but are not limited to, alcohols and mixtures of alcohols with one or more cosolvents (e.g., but not limited to, tert-butyl methyl ether and dichloromethane). The ratio of ethanol to dichloromethane is selected to crystallize the desired compound. The ratio can range from about 5:1 to about 1:5 (v / v). Suitable conditions can also include the addition of an acid. An example of such an acid is hydrochloric acid. Alternatively, other solvent systems, such as a combination of a protic and an aprotic solvent, can be used. In some embodiments, seed crystals are added to catalyze the crystallization process while the solution is cooling. Seed crystals may include or exclude sodium sulfate, the desired compound in crystalline form, or sodium chloride.

[0065] As used herein, the term "protic solvent" refers to a solvent that is capable of dissociating H + or refers to a solvent containing a group capable of forming a hydrogen bond (e.g., a hydroxyl group or an amine group). Examples include water, methanol, ethanol, isopropanol, formic acid, hydrogen fluoride, and ammonia. Preferred protic solvents include alcohols, such as methanol.

[0066] As used herein, the term "aprotic solvent" refers to a solvent that does not contribute to hydrogen bonding under normal reaction conditions for the selected reaction, examples of which are HMPA, acetone, THF (tetrahydrofuran), diethyl ether, acetonitrile, DMF (dimethylformamide), DMSO (dimethyl sulfoxide), chloroform, and DCM (dichloromethane).

[0067] The compounds described herein can be prepared by processes or methods of organic synthetic chemistry. Furthermore, in the schemes described herein, where specific bases, acids, reagents, solvents, coupling agents, etc. are recited, it is understood that other bases, acids, reagents, solvents, coupling agents, etc. can be used unless otherwise specified and are therefore within the scope of the present invention. Variations in reaction conditions, such as temperature and / or reaction duration, which can be used as known in the art, are also within the scope of the present invention. All isomers of the compounds described in these schemes are also encompassed within the scope of the present invention unless otherwise specified. The methods provided herein are as shown in Scheme 1 and Scheme 2. Unless otherwise specified, the temperature at which the reactions of Scheme 1 or Scheme 2 are carried out is not critical. In certain embodiments, when a temperature is specified in a reaction, the temperature may vary from plus or minus about 0.1°C, about 0.5°C, about 1°C, about 5°C, or about 10°C. The optimum temperature may vary depending on which solvent is used in a particular reaction. In carrying out the reactions provided herein, the rate and order of addition of reactants are not critical unless otherwise specified. Unless otherwise specified, reactions are carried out at ambient atmospheric pressure. Unless otherwise specified, the exact amount of reactants is not critical. In some embodiments, the amount of reactants may vary by about 10 mol % or about 10 wt %.

[0068] In some embodiments, the present disclosure provides a synthetic route to Compound-A that is economically feasible for scale-up and therefore commercially viable. The synthetic route to Compound-A described herein does not require a column chromatography purification step, which would otherwise be a costly operation to achieve commercial quantities of Compound-A. The inventors have surprisingly developed a synthetic route to Compound-A that requires an additional step beyond that described in WO 2013 / 124828, but results in a substantially higher overall yield than the reference method due to the elimination of the yield-destroying column chromatography step. The synthetic route described herein is also designed to eliminate the use of pyrophoric compounds and direct hydrogen gas injection, resulting in a safer method for producing Compound-A. In some embodiments, sodium bis(2-methoxyethoxy)aluminum hydride (such as sodium bis(2-methoxyethoxy)aluminum hydride, known under the trade name Vitride™) is used as the reducing agent. Sodium bis(2-methoxyethoxy)aluminum hydride is a non-pyrophoric reducing agent, but is otherwise functionally equivalent to lithium aluminum hydride (lithium aluminum hydride is not used in the methods described herein). In some embodiments, aqueous / organic formate salts (e.g., ammonium formate) are used as an indirect hydrogen source in place of hydrogen gas for Pd-C catalyzed hydrogenation. Without being bound by theory, it is believed that the formate salt dissociates in solution to generate hydrogen, which then transiently binds to the surface of the Pd catalyst and serves as the hydrogenation source.

[0069] Compound-A of the formula:

[0070] [ka]

[0071] (as shown in Scheme-1), 1) reducing Compound-1 to Compound-2 using 5% Pd / C and ammonium formate in a methanol-ethyl acetate solvent system with heating at about 33°C to about 34°C; 2) deprotecting the Boc-protected amine group of compound-2 by refluxing compound-2 with 6N HCl in methanol to give compound-3; 3) hydrolyzing the ester group of Compound-3 by heating Compound-3 with 10N NaOH in methanol-THF at about 55°C to give crude Compound-4, which is further purified by recrystallization using ethanol:DCM (5:1 v / v) solvent system followed by recrystallization using isopropanol to give diastereomerically pure Compound-4; 4) Converting Compound-4 to its hydrochloride salt (Compound-A) using 2N aqueous HCl Provided herein is a method of preparation comprising:

[0072] [ka]

[0073] Compound-B of the formula:

[0074] [ka]

[0075] (as shown in Scheme-1A), comprising the following steps: 1) hydrolyzing the ester group of Compound-3 by heating Compound-3 with 10N NaOH in methanol-THF at about 55° C. to give crude Compound-4′; 2) converting Compound-4' into its hydrochloride salt (Compound-B) using 2N aqueous HCl Provided herein is a method of preparation comprising:

[0076] [ka]

[0077] A process for preparing Compound-1 (as shown in Scheme-2), 1) reducing Compound-5 using a solution of sodium bis(2-methoxyethoxy)aluminum hydride (such as sodium bis(2-methoxyethoxy)aluminum hydride known under the trade name Vitride™) in toluene (70% w / w) in methanol-THF under heating at about 85° C. to obtain the reduction product of Compound-5, which is then treated with concentrated HCl to obtain Compound-6; 2) protecting the free amino group of Compound-6 by using Boc anhydride in the presence of tripotassium phosphate in DCM-water solvent system to give Compound-7; 3) oxidizing compound-7 using potassium permanganate and magnesium sulfate in an acetone-water solvent system to obtain compound-8; 4) reacting Compound-8 with N-phenyl-bis(trifluoromethanesulfonimide) (PhNTf2) in the presence of potassium bis(trimethylsilyl)amide (KHMDS) and hexamethylphosphoramide (HMPA) in THF at −83° C. to give Compound-9; 5) coupling of compound-9 with methyl 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate in the presence of tetrakis(triphenylphosphine)palladium(0) and tripotassium phosphate in THF under reflux conditions to give compound-1; Also provided herein is a method of preparation comprising:

[0078] [ka]

[0079] Manufacturing and Purity Compounds of the present disclosure, including Compound-4 and Compound-A, can be prepared as described above. The compounds of the present disclosure can be produced relatively safely on a large scale because they do not require an external gas hydrogenation step. In some embodiments, the compounds of the present disclosure can be produced at a final product scale of 1 kg, 10 kg, 100 kg, 1000 kg, 10,000 kg, or 100,000 kg, or at any scale between the aforementioned scales, in large-scale production.

[0080] In some embodiments, the compounds of the present invention are substantially pure. By substantially pure, it is meant that the compound contains less than about 5%, 4%, 3%, 2%, 1%, 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1%, preferably less than about 0.1%, of any impurities. In some embodiments, the total impurities, including unreacted reactants or by-products (e.g., compound 3 after reaction to synthesize compound 4), are 0.1-5% or less. The amount of impurities can be measured using HPLC (including RP-HPLC, HPLC-MS, HPLC-MS / MS, HPLC-UV, and IEX) according to methods understood in the art. [Example]

[0081] The present invention is illustrated in more detail by the examples set forth herein, but the present invention should not be construed as being limited thereto.

[0082] The compounds of the present invention can be made by the methods and processes described in the reaction schemes shown below.

[0083] The starting materials and reagents used in the preparation of these compounds are available from commercial suppliers, such as Aldrich Chemical Co. (Milwaukee, Wis.), Bachem (Torrance, Calif.), or Sigma (St. Louis, Mo.), or are prepared by methods known to those skilled in the art according to procedures described in references such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991), Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplements (Elsevier Science Publishers, 1989), Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition), and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989). These schemes are merely illustrative of some of the ways in which the compounds of the present invention may be synthesized, and various modifications to these schemes may be made which will be suggested to one of skill in the art upon reading this disclosure.

[0084] Unless otherwise specified, the reactions described herein are carried out at atmospheric pressure over a temperature range of about -78°C to about 150°C, more preferably about 0°C to about 125°C, and most preferably about 10°C to about 40°C.

[0085] In the reactions described below, reactive functional groups, such as hydroxy, amino, imino, thio, or carboxy groups, may need to be protected if desired in the final product to avoid their undesired participation in the reaction. Conventional protecting groups can be used in accordance with standard practice. See, for example, T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Chemistry," John Wiley and Sons, Inc., 1999.

[0086] Example 1 Synthesis, purification, and characterization of compound-A Step-1: (R)-N-((R)-chroman-2-ylmethyl)-1-(naphthalen-1-yl)ethanamine: hydrochloride

[0087] [ka]

[0088] To a solution of (R)-N-((R)-1-(naphthalen-1-yl)ethyl)chroman-2-carboxamide (1.0 eq) in 2-MeTHF (5.0 v) under nitrogen, a toluene solution (70% w / w) (2.6 eq) of sodium bis(2-methoxyethoxy)aluminum hydride (such as sodium bis(2-methoxyethoxy)aluminum hydride, known under the trade name Vitride®) was added over 1 hour at 5±5°C. The reaction mixture was stirred at room temperature for 1 hour and then heated to 85±5°C for 6 hours. The reaction mass was cooled to 10±5°C and the excess sodium bis(2-methoxyethoxy)aluminum hydride (such as sodium bis(2-methoxyethoxy)aluminum hydride, known under the trade name Vitride®) was quenched using ethyl acetate (2.0 eq). This was then stirred for 30 minutes. Purified water (1.0 eq) was added to the solution and stirred for 1 hour. A 5N aqueous solution of NaOH (5.0 v) was added to the above reaction mass at 20 ± 5 °C and stirred for another 30 minutes. The organic phase was separated, and the aqueous phase was extracted with MTBE (4.0 v) and again with MTBE (2.0 v). The combined organic phase was washed with saturated brine solution (5.0 v). The organic phase was separated and evaporated under vacuum at 40 ± 5 °C to approximately 5-7 v. Concentrated HCl (1.5 eq) was added to the above reaction mixture at 10 ± 5 °C and stirred for 2 hours. The precipitated solid was filtered and washed with purified water (0.5 v) and MTBE (0.5 v). The wet cake was then dried in a vacuum oven at 40 ± 5 °C for 10 hours to obtain (R)-N-((R)-chroman-2-ylmethyl)-1-(naphthalen-1-yl)ethanamine hydrochloride. Yield: 92.9% Mass:318.0 [MH+] 1H NMR (300 MHz, DMSO-d6) δ: 10.21-9.64 (bs, 2H), 8.29 - 8.26 (d, J = 8.1 Hz, 1H), 8.10 - 7.98 (m, 3H), 7.66-7.58 (m, 3H), 7.11 - 7.06 (m, 2H), 6.86-6.76 (m, 2H), 5.45 (bs, 1H), 4.49 - 4.46 (m, 1H), 3.34-3.17 (m, 2H), 2.86-2.66 (m, 2H), 2.06- 2.00 (m, 1H), 1.76 - 1.74 (d, J = 6.6Hz, 3H), 1.70-1.57 (m, 1H).

[0089] Compound-6 can be isolated as the free base by the following procedure: To a solution of (R)-N-((R)-1-(naphthalen-1-yl)ethyl)chroman-2-carboxamide (1.0 eq) in 2-MeTHF (5.0 eq) under nitrogen, a toluene solution (70% w / w) (2.6 eq) of sodium bis(2-methoxyethoxy)aluminum hydride (such as sodium bis(2-methoxyethoxy)aluminum hydride, known under the trade name Vitride®) was added over 1 h at 5±5°C. The reaction mixture was stirred at room temperature for 1 h and then heated to 85±5°C for 6 h. The reaction mass was cooled to 10±5°C, and the excess sodium bis(2-methoxyethoxy)aluminum hydride (such as sodium bis(2-methoxyethoxy)aluminum hydride, known under the trade name Vitride®) was quenched using ethyl acetate (2.0 eq). The mixture was then stirred for 30 min. Purified water (1.0 eq) was added to the above solution and stirred for 1 hour. 5N NaOH aqueous solution (5.0 v) was added to the above reaction mass at 20±5°C and stirred for another 30 minutes. The organic phase was separated and the aqueous phase was extracted with MTBE (4.0 v) and again with MTBE (2.0 v). The combined organic phase was washed with a saturated solution of brine (5.0 v). The organic phase was separated and evaporated under vacuum at 40±5°C to about 5-7 v. The above mass was wiped with ethanol (2 v) and fresh ethanol (3 v) was added to obtain a clear solution at 40±5°C. It was cooled to 25-30°C and stirred for 1 hour. It was then cooled to 0-5°C, the precipitated solid was filtered and washed with ice-cold ethanol (1v), and the wet solid was then dried in a vacuum oven at 50±5°C for 14 hours to give (R)-N-((R)-chroman-2-ylmethyl)-1-(naphthalen-1-yl)ethanamine. Yield: 75.98% Mass:318.46 [MH+] 1H NMR (400 MHz, DMSO-d6) δ: 8.34 - 8.27 (m, 1H), 7.93 (dd, J = 7.9, 1.7 Hz, 1H), 7.80 (d, J = 8.1 Hz, 1H), 7.73 (dd, J = 7.3, 1.2 Hz, 1H), 7.58 - 7.46 (m, 3H), 7.07 - 6.99 (m, 2H), 6.78 (td, J = 7.4, 1.2 Hz, 1H), 6.71 (dd, J = 8.5, 1.2 Hz, 1H), 4.73 - 4.58 (m, 1H), 4.09 (dtd, J = 9.9, 6.0, 2.2 Hz, 1H), 2.77 (ddt, J = 19.0, 14.2, 6.9 Hz, 2H), 2.70 - 2.54 (m, 2H), 2.35 (s, 1H), 2.11 - 1.97 (m, 1H), 1.61 (dddd, J = 13.5, 11.1, 9.9, 5.5 Hz, 1H), 1.42 (d, J = 6.5 Hz, 3H).

[0090] Engineering-2:tert-ブチル((R)-クロマン-2-イルメチル)((R)-1-(ナフタレン-1-イル)エチル)カルバメート

[0091]

change

[0092] To a solution of (R)-N-((R)-chroman-2-ylmethyl)-1-(naphthalen-1-yl)ethanamine (1.0 eq) in DCM (4.0 v) was added a solution of KPO (1.5 eq) in purified water (3.0 v) at 15 ± 5 °C. To the above solution, 1.1 eq of (Boc)O dissolved in DCM (1.0 v) was added at the same temperature. The above solution was stirred at 25 ± 5 °C for 18 h. The organic phase was separated and evaporated under vacuum to approximately 2.0 v. DCM (dichloromethane) was replaced with ethanol (1.0 v). Fresh ethanol (3 v) was added to this solution and heated to 50 ± 5 °C to obtain a clear solution, which was then cooled to room temperature and stirred at 0 ± 5 °C for 1 h. The precipitated product was filtered and washed with ice-cold ethanol (1 v). The wet solid was dried in a vacuum tray dryer for 16 hours to give the product tert-butyl ((R)-chroman-2-ylmethyl)((R)-1-(naphthalen-1-yl)ethyl)carbamate. Yield: 98% Mass: 440.13[M+Na] 1 H NMR (400 MHz, DMSO-d6) δ: 8.06 (bs, 1H), 7.96 (dd, J = 7.7, 1.8 Hz, 1H), 7.89 (d, J = 8.2 Hz, 1H), 7.69 (d, J = 7.1 Hz, 1H), 7.62 - 7.47 (m, 3H), 6.96 - 6.85 (m, 1H), 6.82 (dd, J = 7.6, 1.6 Hz, 1H), 6.66 (td, J = 7.4, 1.3 Hz, 1H), 6.21 (s, 1H), 3.18 (s, 2H), 2.65 (s, 2H), 2.38 (d, J = 16.7 Hz, 1H), 1.81 (s, 1H), 1.64 (d, J = 6.8 Hz, 3H), 1.53 - 1.43 (m, 9H), 1.35 - 1.10 (m, 2H).

[0093] Step-3: tert-butyl ((R)-1-(naphthalen-1-yl)ethyl)(((R)-4-oxochroman-2-yl)methyl)carbamate

[0094] [ka]

[0095] A solution of tert-butyl ((R)-chroman-2-ylmethyl) ((R)-1-(naphthalen-1-yl)ethyl)carbamate (1.0 eq) in acetone (25.0 v) and purified water (6.0 v) was heated to 42±5°C. To this solution, MgSO4 (3.5 eq) and then KMnO4 (7.0 eq) were added portionwise over approximately 3 hours. The reaction mass was stirred at the same temperature for 8 to 16 hours. The reaction mass was cooled to 15±5°C. A saturated aqueous solution of Na2SO3 (0.84 w / w) was added at the same temperature. This was stirred for 30 minutes. Diatomaceous earth (1.0 w / w) was added to the reaction mass and stirred at 35±5°C for 1 hour. The mixture was centrifuged, and the filter cake was added to a reactor containing acetone (7.85 w / w) and refluxed for 3 hours. The reaction mass was filtered and concentrated to about 6.0 v. To this was added a saturated solution of brine (1.20 w / w). The product was extracted with ethyl acetate (10.0 v x 2). The organic layer was separated and washed with brine (2.4 w / w). The organic layer was separated and evaporated under vacuum to about 3.0 v. THF (3.0 v) was added to the above and concentrated to give tert-butyl ((R)-1-(naphthalen-1-yl)ethyl)(((R)-4-oxochroman-2-yl)methyl)carbamate. Yield: 99% Mass: 454.12[M+Na] 1H NMR (400 MHz, DMSO-d6) δ: 8.10 - 8.00 (m, 1H), 7.97 (dd, J = 7.9, 1.6 Hz, 1H), 7.90 (d, J = 8.1 Hz, 1H), 7.69 (d, J = 7.2 Hz, 1H), 7.60 - 7.50 (m, 4H), 7.37 (ddd, J = 8.7, 7.2, 1.8 Hz, 1H), 6.92 (td, J = 7.6, 1.0 Hz, 1H), 6.18 (d, J = 8.3 Hz, 1H), 3.66 (tt, J = 8.1, 4.9 Hz, 1H), 3.40 - 3.21 (m, 3H), 2.44 (d, J = 14.4 Hz, 1H), 2.25 (dd, J = 17.0, 3.2 Hz, 1H), 1.64 (d, J = 6.8 Hz, 3H), 1.48 (d, J = 12.2 Hz, 9H).

[0096] Step-4: (R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-2H-chromen-4-yl trifluoromethanesulfonate

[0097] [ka]

[0098] To a solution of tert-butyl ((R)-1-(naphthalen-1-yl)ethyl)(((R)-4-oxochroman-2-yl)methyl)carbamate (1.0 eq) in THF (7.0 v) was added HMPA (0.0015 v) under nitrogen. Potassium bis(trimethylsilyl)amide (KHMDS) solution (1 M in THF) (1.5 eq) was added dropwise to the above solution over 1 hour 30 minutes at -83±5°C. The reaction mass was stirred for 45 minutes at -83±5°C. A solution of N-phenyl-bis(trifluoromethanesulfonimide) (PhNTf2) (1.5 eq) in THF (4.0 v) was added dropwise over 3 hours 10 minutes at the same temperature. This was stirred for another 30 minutes. The reaction was quenched using purified water (1.5v) at −20±10° C. to give (R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-2H-chromen-4-yl trifluoromethanesulfonate, which was used directly in the next step.

[0099] Alternative isolation procedure: Upon completion of the reaction, the mass was quenched with purified water (1.5 v) at −20±10° C. The THF was concentrated, and then the product was extracted with n-hexane (5 v × 3), and the combined extracts were washed with water (5 v) and concentrated to give (R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-2H-chromen-4-yl trifluoromethanesulfonate. Yield: 84% Mass: 586.0[M+Na] 1H NMR (400 MHz, DMSO-d6) δ: 8.00 (dt, J = 6.9, 3.5 Hz, 2H), 7.97 - 7.88 (m, 1H), 7.68 (s, 1H), 7.57 (ddd, J = 8.7, 6.9, 3.0 Hz, 3H), 7.22 (t, J = 7.7 Hz, 1H), 7.05 (dd, J = 7.7, 1.6 Hz, 1H), 6.96 (td, J = 7.6, 1.1 Hz, 1H), 6.45 (s, 1H), 6.09 (s, 1H), 5.30 (s, 1H), 3.95 (s, 1H), 1.63 (d, J = 6.9 Hz, 3H), 1.39 (s, 9H), 1.24 (s, 2H).

[0100] Step-5: methyl 5-((R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-2H-chromen-4-yl)-2-methylbenzoate

[0101] [ka]

[0102] (R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-2H-chromen-4-yl trifluoromethanesulfonate in THF (1.0 eq) was added to a reactor under nitrogen. To the above solution, methyl 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (0.95 eq) and K3PO4 (1.5 eq) were added. Pd(PPh3)4 (1.2 mol%) was added to the above solution at room temperature under nitrogen. The reaction mixture was heated to reflux temperature for 12-18 hours. The reaction mass was cooled to room temperature, and to it was added Celite (1 w / w), n-heptane (3.0 v), and water (1.0 v). The above reaction mass was filtered, the layers separated and the aqueous phase further extracted with MTBE (2.0 v).

[0103] To the combined organic phase, activated carbon (0.2 w / w), silica gel (1.0 w / w), and Celite (1.0 w / w) were added. The mixture was stirred at room temperature for 3 hours. The mixture was filtered, and the reaction mass was evaporated under vacuum to about 2 v. Isopropyl alcohol (2.0 v) was added to the reaction mass and evaporated to about 2.0 v. This co-distillation process was repeated again. The mass was cooled to 5 ± 5 °C, stirred at the same temperature for 4 to 8 hours, and filtered to obtain methyl 5-((R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-2H-chromen-4-yl)-2-methylbenzoate as a wet cake.

[0104] The cake was stirred in isopropyl alcohol (2.0 v) and heated to 68 ± 5 °C to obtain a clear solution. It was then cooled to 15 ± 5 °C and stirred at the same temperature for 16 hours. The precipitated solid was filtered and washed with isopropyl alcohol (0.5 v). The solid was dried under vacuum at 40 ± 5 °C until the LOD was ≤ 0.5%.

[0105] The above solid was added to a reactor containing ethyl acetate (3.15 v). The resulting solution was filtered through a microporous filter. The ethyl acetate layer was washed with purified water (1.5 w / w) for 10 minutes. The organic phase was separated and washed again with purified water (1.5 w / w). The organic phase was separated and evaporated under vacuum at 40 ± 5 °C to approximately 1.5-2 v. The residue was co-distilled twice with isopropyl alcohol (or ethanol) (1.57 v) to approximately 1.5-2 v. Purified water (3.0 w / w) was added to the above solution. The isopropyl alcohol was distilled off by evaporation under vacuum at 40 ± 5 °C to approximately 3.5-4 v. The precipitated solid was filtered and washed with water (0.5 v). The solid thus obtained was dried in a vacuum oven at 45±5° C. until LOD≦0.5% to give methyl 5-((R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-2H-chromen-4-yl)-2-methylbenzoate. Yield: 56.81% Mass: 586.44 [M+Na] 1 1H NMR (400 MHz, DMSO-d6) δ: 8.08 (d, J = 8.0 Hz, 1H), 7.97 (dd, J = 8.1, 1.4 Hz, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.68 (d, J = 7.2 Hz, 1H), 7.65 - 7.49 (m, 4H), 7.35 (d, J = 7.9 Hz, 1H), 7.21 (s, 1H), 7.10 - 7.02 (m, 1H), 6.81 - 6.69 (m, 2H), 6.38 (bs, 1H), 6.11 (bs, 1H), 5.19 (bs, 1H), 3.85 (s, 3H), 3.75 (bs, 1H), 3.31(m, 1H), 2.53 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H), 1.50 (bs, 1H), 1.32 (bs, 9H).

[0106] Alternative procedure: To a solution of the above (R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-2H-chromen-4-yl trifluoromethanesulfonate (110 g, 195 mmol) in a mixture of THF (volume: 500 ml, ratio: 2.000) and water (volume: 250 ml, ratio: 1.000), methyl 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate (51.2 g, 185 mmol), tribasic potassium phosphate (91 g, 429 mmol), and tetrakis (1.128 g, 0.976 mmol) were added sequentially under nitrogen. The mixture was heated to reflux for 18 hours. The progress of the reaction was monitored by HPLC. After complete consumption of SM, the mass was filtered through a Celite pad and concentrated under reduced pressure. The residue was diluted with water, and the product was extracted with n-hexane (5 v × 3 times). The combined extracts were washed with water (5 v) and concentrated under reduced pressure. The above residue was co-distilled with ethanol (2 v), and then fresh ethanol (4 v) was added, and the resulting mixture was warmed to obtain a clear solution. It was cooled to room temperature and stirred for 18 hours. The mass was cooled to 0 ± 5 °C with stirring for 1 hour, and the product thus crystallized was filtered, and the solid was washed with ice-cold ethanol (1 v). The solid thus obtained was dried in a vacuum oven at 45 ± 5 °C until the LOD was ≦ 0.5% to obtain methyl 5-((R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-2H-chromen-4-yl)-2-methylbenzoate. Yield: 82% Mass: 586.44 [M+Na] 1H NMR (400 MHz, DMSO-d6) δ: 8.08 (d, J = 8.0 Hz, 1H), 7.97 (dd, J = 8.1, 1.4 Hz, 1H), 7.91 (d, J = 8.2 Hz, 1H), 7.68 (d, J = 7.2 Hz, 1H), 7.65 - 7.49 (m, 4H), 7.35 (d, J = 7.9 Hz, 1H), 7.21 (s, 1H), 7.10 - 7.02 (m, 1H), 6.81 - 6.69 (m, 2H), 6.38 (bs, 1H), 6.11 (bs, 1H), 5.19 (bs, 1H), 3.85 (s, 3H), 3.75 (bs, 1H), 3.31(m, 1H), 2.53 (s, 3H), 1.65 (d, J = 6.8 Hz, 3H), 1.50 (bs, 1H), 1.32 (bs, 9H).

[0107] Step-6: methyl 5-((2R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)-2-methylbenzoate

[0108] [ka]

[0109] Ammonium formate (10.0 eq) was dissolved in methanol and heated to 33-34°C (6.0 v) to give a clear solution. Methyl 5-((R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-2H-chromen-4-yl)-2-methylbenzoate (1.0 eq) was dissolved in ethyl acetate (3.0 v) and heated to 33-34°C, and 5% Pd / C 50% wet (10% w / w) was added. The ammonium formate solution was then added to the above suspension via an addition funnel over 6 h. The reaction mixture was heated at 33-34°C for 2 h 30 min. The reaction mixture was cooled to 20°C over 4 h and stirred at 20°C for 9 h. The catalyst was filtered off through a GF / F glass microfiber filter and washed with methanol (1.0 v) and then with ethyl acetate (2.0 v). The solution was successively concentrated at 250 mbar and diluted with ethyl acetate to reach a molar ratio of 25 / 75 methanol / ethyl acetate (NMR). To the white suspension thus obtained, ethyl acetate (4.0 v) and then water (8.0 v) were added, allowing for easy separation of the two homogeneous layers. The organic layer was washed with water (8.0 v), then successively concentrated at 250 mbar and diluted with methanol to remove the ethyl acetate (NMR). The intermediate methyl 5-((2R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)-2-methylbenzoate was isolated as a methanol solution (approximately 3.0 v) and was ready for the next step of the synthesis. Yield: 100% Mass: 588.25 [M+Na] 1H NMR (400 MHz, DMSO-d6) δ: 8.05 (dd, J = 8.1, 1.5 Hz, 2H), 7.94 (d, J = 8.2 Hz, 1H), 7.72 (d, J = 7.1 Hz, 1H), 7.69 - 7.48 (m, 3H), 7.34 (d, J = 2.0 Hz, 1H), 7.24 (d, J = 7.9 Hz, 1H), 6.98 (dd, J = 7.8, 2.0 Hz, 1H), 6.92 (t, J = 7.3 Hz, 1H), 6.59 (td, J = 7.5, 1.3 Hz, 1H), 6.33 (s, 1H), 6.27 (d, J = 7.7 Hz, 1H), 6.14 (s, 1H), 3.83 (s, 3H), 3.21 (dd, J = 14.4, 5.9 Hz, 2H), 2.48 (s, 3H), 1.66 (s, 3H), 1.48 (bs, 2H), 1.37 (bs, 9H), 1.24 (s, 2H).

[0110] Step-7: Methyl 2-methyl-5-((2R)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoate hydrochloride

[0111] [ka]

[0112] A solution of methyl 5-((2R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)-2-methylbenzoate (300 g, 530 mmol, 1.0 eq) in methanol (1.2 L, 4.0 v) was heated to reflux (63° C.). 6 N aqueous HCl (approximately 352 mL, 2121 mmol, 4.0 eq) was added to the reaction mixture via a dropping funnel at 63° C. over 2 hours. The solution was stirred at 63° C. for an additional hour, cooled to 20° C. at a rate of −10° C. / hour, and then stirred at 20° C. for 7 hours. The white suspension was filtered and the solid washed first with methanol (225 mL, 0.75 v) and then with water [2 × 300 mL (1 v)] to give methyl 2-methyl-5-((2R)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoate hydrochloride as a wet white hydrochloride salt, which was ready for the next step of the synthesis. Yield: 98% Mass: 466.12 [MH+] 1H NMR (400 MHz, DMSO-d6) δ: 8.34 - 8.24 (m, 1H), 7.96 - 7.88 (m, 1H), 7.78 (d, J = 8.1 Hz, 1H), 7.72s (dd, J = 7.2, 1.2 Hz, 1H), 7.63 (d, J = 1.3 Hz, 1H), 7.56 - 7.44 (m, 3H), 7.27 (d, J = 1.2 Hz, 2H), 7.06 (tdd, J = 7.1, 2.0, 1.0 Hz, 1H), 6.79 (dd, J = 8.2, 1.3 Hz, 1H), 6.71 (td, J = 7.5, 1.3 Hz, 1H), 6.52 (dt, J = 7.7, 1.4 Hz, 1H), 4.67 (q, J = 6.5 Hz, 1H), 4.35 - 4.12 (m, 2H), 3.78 (s, 3H), 2.79 (dd, J = 12.2, 6.1 Hz, 1H), 2.64 (dd, J = 12.3, 5.4 Hz, 1H), 2.49 (s, 3H), 2.22 (ddd, J = 13.5, 5.8, 1.7 Hz, 1H), 1.85 - 1.69 (m, 1H), 1.41 (d, J = 6.5 Hz, 3H).

[0113] Engineering-8:2-メチル-5-((2R,4S)-2-((((R)-1-(ナフタレン-1-イル)エチル)アミノ)メチル)クロマン-4-イル)benzoic acid acid

[0114]

change

[0115] Methyl-2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoate hydrochloride (260 g, 518 mmol, 1.0 eq) was dissolved in a mixture of methanol (1.48 L, 5.7 v) and tetrahydrofuran (1.48 L, 5.7 v). The solution was heated to 55 °C, and 10 N NaOH (approximately 260 mL, 2589 mmol, 5.0 eq) was added over 20 min. The clear solution was stirred at 55 °C for 2 h (pH 10). The reaction mixture was cooled to 30 °C and diluted with water (1.82 L, 7.0 v). The pH was adjusted to 6-7 by slow addition of 2 N aqueous HCl (1062 mL, 2124 mmol, 4.1 eq). The zwitterion was precipitated, and the suspension was cooled to 20 °C and stirred at this temperature for 30 min. The sandy solid was easily filtered and washed first with water [2 × 1300 mL (5 v)], then with EtOH (520 mL, 2.0 v), and then with isopropyl alcohol (IPA) (260 mL, 1.0 v). The white solid was dried in vacuo at 40 °C for 20 h to give 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid (crude, 225 g). Yield: 96.15% Purity:83.79:15.57%

[0116] Purification: Crude 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid (225 g, 498 mmol, 1.0 eq) was suspended in a 5:1 ethanol / dichloromethane solvent mixture (5.4 L, 24.0 v). The suspension was heated vigorously to reflux (60 °C) to complete dissolution of the material. Subsequent recrystallization began before dissolution was complete. The suspension was stirred at 60 °C for 10 min, then cooled to 20 °C at a rate of -20 °C / h, filtered, and washed first with a 5:1 ethanol / dichloromethane solvent mixture (2 × 675 mL, 3 v) and then with ethanol (225 mL, 1 v). The white solid was dried at 40° C. overnight to give 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid as a white solid. Yield: 64.1% (150g) Purity:99.70:0.20%

[0117] Preparation of the hydrochloride salt: The diastereomeric pure 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid thus obtained (150 g, 332 mmol, 1.0 eq) was suspended in water (2.55 L, 17 v). After heating the reaction mass to 30° C., 2N aqueous NaOH solution (approximately 300 mL, 598 mmol, 1.8 eq) was quickly added to completely dissolve the compound. The solution was filtered through a GF / A glass microfiber filter to remove any solid impurities. Then, 2N aqueous HCl solution (665 mL, 1329 mmol, 4 eq) was added at the same temperature, resulting in the precipitation of a large amount of white solid that was difficult to stir. The reaction mass was stirred at room temperature (22° C.) for 20 hours. The resulting slurry was filtered and washed with water [1500 mL (10 v), then 3 × 600 mL (4 v)] until the pH of the filtrate was 6. After 65 h in an oven at 40 °C, 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid hydrochloride was obtained as a white solid in quantitative yield. Yield: 89.53 % Purity: 99.63 % Mass: 452.18 [MH+] 1H NMR (DMSO-d6) δ: 12.76 (bs, 1H), 10.07 (bs, 1H), 9.64 (bs, 1H), 8.30 (d, J = 8.4 Hz, 1H), 8.14 - 7.93 (m, 3H), 7.73 - 7.56 (m, 4H), 7.33 - 7.20 (m, 2H), 7.14 (t, J = 7.6 Hz, 1H), 6.87 (dd, J = 8.2, 1.0 Hz, 1H), 6.79 (td, J = 7.6, 1.1 Hz, 1H), 6.57 (d, J = 7.7 Hz, 1H), 5.48 (bs, 1H), 4.68 (m, 1H), 4.29 (dd, J = 12.0, 5.7 Hz, 1H), 3.30 (d, J = 8.6 Hz, 1H), 3.20 (d, J = 12.8 Hz, 1H), 2.48 (s, 3 H), 2.24 (dd, J = 12.7, 5.3 Hz, 1H), 1.92 (q, J = 12.1 Hz, 1H), 1.77 (d, J = 6.6 Hz, 3H). IR (KBr, cm-1): 3057.55, 2956.04, 2876.08, 2767.21, 2681.29, 2499.80, 2481.85, 2298.48, 2202.11, 1711.42, 1595.25, 1579.33, 1517.30, 1497.94, 1483.60, 1451.74, 1400.13, 1379.30, 1362.67, 1300.55, 1279.31, 1238.73, 1217.88, 1187.99, 1175.75, 1118.41, 1089.60, 1072.72, 1020.79, 972.36, 928.79, 913.23, 892.94, 860.86, 797.19, 780.99, 745.77, 704.12, 667.76, 611.33, 571.04, 543.00, 528.59, 470.53, 435.58, 416.04, 401.77.

[0118] The PXRD (powder X-ray diffraction pattern) peaks in Table 1 are tabulated from those shown in FIG.

[0119] [Table 1]

[0120] As noted above, the amount of impurities can be measured using HPLC (including RP-HPLC, HPLC-MS, HPLC-MS / MS, HPLC-UV, and IEX) according to methods understood in the art. For example, Figures 2 and 3 show example HPLC chromatograms, and the corresponding peak tables are shown in Tables 2 and 3, respectively. Each peak table discloses information about Compound-A and Compound-B.

[0121] [Table 2]

[0122] [Table 3]

[0123] Below are the experimental details of RP-HPLC for Figures 2 and 3. RP-HPLC: Column: YMC Triart (250 × 4.6) mm, 5 μm, Analysis time (min): 55.00, injection volume: 5.00μL, Wavelength: WVL: 220 nm, flow rate: 1.00 ml / min, column temperature: 40.0°C, Mobile phase A: 10 mM NH4OAc, pH-10.0:ACN (90:10), and Mobile phase B: CAN: 10mM NH4OAc, pH-10.0 (90:10).

[0124] In some embodiments, the present disclosure provides:

[0125] A1. A method for synthesizing compound A

[0126] [ka]

[0127] A method in which the synthesis does not require pyrophoric reagents.

[0128] A2. The method according to A1, wherein the synthesis comprises the steps of: 1) Reduction of Compound-1 to obtain Compound-2 using 5% Pd / C and ammonium formate in a methanol-ethyl acetate solvent system with heating at 33°C-34°C.

[0129] [ka]

[0130] 2) deprotecting the Boc-protected amine group of compound-2 by refluxing compound-2 with 6N HCl in methanol to give compound-3.

[0131] [ka]

[0132] 3) Hydrolysis of the ester group of Compound-3 by heating Compound-3 with NaOH in methanol-THF at 55° C. to give crude Compound-4, which is further purified by recrystallization using ethanol:DCM (5:1) solvent system followed by recrystallization using isopropanol to give diastereomerically pure Compound-4.

[0133] [ka]

[0134] and 4) Converting Compound-4 to its hydrochloride salt (Compound-A) using 2N aqueous HCl

[0135] [ka]

[0136] A method comprising:

[0137] A3. A method for synthesizing compound-1, comprising: a) reduction of the amide group of Compound-5 using sodium bis(2-methoxyethoxy)aluminum hydride (such as sodium bis(2-methoxyethoxy)aluminum hydride known under the trade name Vitride™) in toluene, followed by hydrochloride salt formation using concentrated HCl to give Compound-6;

[0138] [ka]

[0139] b) protecting the free amino group of compound-6 using Boc anhydride (di-tert-butyl dicarbonate) and tripotassium phosphate to give compound-7

[0140] [ka]

[0141] c) oxidizing Compound-7 using KMnO4 and MgSO4 to obtain Compound-8

[0142] [ka]

[0143] d) reacting compound-8 with a triflating agent to obtain compound-9

[0144] [ka]

[0145] and e) coupling compound-9 with methyl 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate in the presence of a palladium catalyst to give compound-1

[0146] [ka]

[0147] A method comprising:

[0148] A4. The method according to A1, wherein the synthesis does not require a purification step by column chromatography to obtain the product.

[0149] A5. The method of A1, wherein the synthesis does not require pyrophoric reagents.

[0150] A6. The method of A1, wherein the synthesis does not require added hydrogen gas.

[0151] A7. The method of A1, wherein the synthesis is carried out on a 1 kg, 10 kg, or 100 kg scale.

[0152] A8. The method according to A4, wherein the synthesis does not require a chiral column chromatography purification method to obtain the product.

[0153] A9. The method of A4, wherein the synthesis does not require pyrophoric reagents.

[0154] A10. A method for obtaining a substantially diastereoisomerically pure composition of compound 4, comprising the step of crystallizing said compound 4 from a mixture of methyl ester compound 3 and compound 4 under suitable crystallization conditions. * * *

[0155] The invention described and claimed herein has many features and embodiments, including but not limited to those illustrated or depicted or referenced in the Detailed Description. Not intended to be comprehensive, the invention described and claimed herein is not limited to or by the features or embodiments set forth in the Detailed Description, which is included for illustrative purposes only and not for limiting purposes. Those skilled in the art will readily recognize that many of the components and parameters can be varied or modified to a certain extent or substituted with known equivalents without departing from the scope of the invention. It is understood that such variations and equivalents are incorporated herein as if individually described. The invention also includes all steps, features, compositions, and compounds referred to or shown in this specification, individually or collectively, and any combination of any two or more of said steps or features.

[0156] All patents, publications, scientific articles, websites, and other documents and materials referenced or described in this specification are indicative of the level of skill of those skilled in the art to which this invention pertains, and each such reference document and material is incorporated herein by reference to the same extent as if it were individually incorporated by reference in its entirety or as if set forth in its entirety herein. Applicants reserve the right to physically incorporate into this specification all materials and information from any such patents, publications, scientific articles, and other referenced materials or documents. The reference herein to any applications, patents, and publications is not and should not be considered as an admission or any form of suggestion that they constitute valid prior art or form part of the common general knowledge in any country in the world.

[0157] The specific methods, processes, and compounds described herein are representative of preferred embodiments and are exemplary and do not limit the scope of the invention. Other objects and embodiments will occur to those skilled in the art upon consideration of this specification, and are encompassed within the spirit of the invention as defined by the claims. Those skilled in the art will readily recognize that various substitutions and modifications can be made to the invention disclosed herein without departing from the scope and spirit of the invention. The invention illustratively described herein can suitably be practiced in the absence of any element or elements, or limitation or limitations, not specifically disclosed herein as essential. Thus, for example, in each instance herein, in an embodiment or example of the invention, any of the terms "comprising," "consisting essentially of," and "consisting of" can be replaced with either of the other two terms herein. Furthermore, terms such as "comprising," "including," and "containing" should be interpreted expansively and without limitation. The methods and processes illustratively described herein may suitably be practiced with different orders of steps and are not necessarily limited to the order of steps set forth in this specification or claims. As used in this specification and the appended claims, the singular forms "a," "an," and "the" also include plural referents unless the context clearly indicates otherwise. In no event should this patent be construed as limited to the particular examples or embodiments or methods specifically disclosed herein. In no event should this patent be construed as limited by any statements made by any Patent and Trademark Office examiner or any other Office officer or employee unless such statements are specifically, unconditionally, or unreservedly adopted in applicants' reply briefs. Furthermore, titles or headings, etc., are provided to enhance the reader's comprehension of this document and should not be construed as limiting the scope of this document. Embodiments of the Invention Described Herein Any examples of components should be considered non-limiting.

[0158] The terms and expressions which have been employed are used as terms of description and not as terms of limitation, and the use of such terms and expressions is not intended to exclude any equivalents of the features or portions thereof shown and described, but it is recognized that various modifications are possible within the scope of the invention as claimed. It is therefore to be understood that while the invention has been specifically disclosed by preferred embodiments and optional features, modifications and variations of the concepts disclosed herein may be resorted to by those skilled in the art, and such modifications and variations are deemed to be within the scope of the invention as defined by the appended claims.

[0159] The invention has been described broadly and generically herein. Each of the narrower subcategory and subgeneric groupings that fall within the generic disclosure also form part of the invention. This includes the generic description of the invention with a proviso or negative limitation that excludes any subject matter from the generic description, regardless of whether the excluded material is specifically described herein.

[0160] Other embodiments are within the scope of the following claims. Additionally, where features or embodiments of the invention are described in terms of Markush groups, those skilled in the art will understand that the invention is also thereby described in terms of individual elements or subgroups of elements of the Markush group.

Claims

1. A method for preparing 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid hydrochloride (Compound-A), comprising the steps of: 【Chemistry 1】 The synthesis involves the following steps: a) reducing methyl 5-((R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-2H-chromen-4-yl)-2-methylbenzoate (Compound-1) using Pd / C and ammonium formate at a temperature between 10° C. and 50° C. to obtain methyl 5-((2R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)-2-methylbenzoate (Compound-2); 【Chemistry 2】 b) Boc deprotection of Compound-2 to obtain the corresponding aminomethyl 2-methyl-5-((2R)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoate hydrochloride (Compound-3) 【Transformation 3】 c) hydrolyzing the ester group of Compound-3 and isolating the pure diastereoisomer using recrystallization to obtain 2-methyl-5-((2R,4S)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid (Compound-4). 【Chemistry 4】 and d) converting compound-4 to its hydrochloride salt 【Transformation 5】 Including, Further, there is provided a method for producing methyl 5-((R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-2H-chromen-4-yl)-2-methylbenzoate (Compound-1), comprising the steps of: A) reduction of the amide group of (R)-N-((R)-1-(naphthalen-1-yl)ethyl)chroman-2-carboxamide (Compound-5) using sodium bis(2-methoxyethoxy)aluminum hydride, followed by acid neutralization to obtain (R)-N-((R)-chroman-2-ylmethyl)-1-(naphthalen-1-yl)ethanamine hydrochloride (Compound-6) 【Transformation 6】 B) Protecting the free amino group of Compound-6 to obtain tert-butyl ((R)-chroman-2-ylmethyl)((R)-1-(naphthalen-1-yl)ethyl)carbamate (Compound-7). 【Transformation 7】 C) Oxidizing Compound-7 to obtain tert-butyl ((R)-1-(naphthalen-1-yl)ethyl)(((R)-4-oxochroman-2-yl)methyl)carbamate (Compound-8). 【Transformation 8】 D) reacting Compound-8 with a triflating agent to obtain (R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-2H-chromen-4-yl trifluoromethanesulfonate (Compound-9). 【Chemistry 9】 and E) coupling Compound-9 with methyl 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate to obtain methyl 5-((R)-2-(((tert-butoxycarbonyl)((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)-2H-chromen-4-yl)-2-methylbenzoate (Compound-1) 【Chemistry 10】 A method of manufacturing, including a method comprising:

2. 10. The method of claim 1, wherein Compound-A is present with the impurity 2-methyl-5-((2R,4R)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid hydrochloride (Compound-B) at an area fraction of less than 1.0% by HPLC.

3. 3. The method of claim 2, wherein the level of the impurity 2-methyl-5-((2R,4R)-2-((((R)-1-(naphthalen-1-yl)ethyl)amino)methyl)chroman-4-yl)benzoic acid hydrochloride (Compound-B) is less than 0.5% area fraction by HPLC.

4. 10. The method of claim 1, wherein step (c) of isolating the pure diastereoisomer by hydrolyzing the ester group of compound-3 and using recrystallization is carried out by heating compound-3 with 10N NaOH in methanol-THF at 55° C. to obtain crude compound-4, which is further purified by recrystallization to obtain diastereoisomerically pure compound-4.

5. 10. The method of claim 1, wherein step (c) of isolating the pure diastereoisomers by using recrystallization is carried out using a solvent mixture consisting of a protic polar solvent and an aprotic polar solvent.

6. 6. The method of claim 5, wherein the protic polar solvent is ethanol, methanol, or isopropanol.

7. 6. The method of claim 5, wherein the aprotic polar solvent is dichloromethane, dimethylformamide, or tetrahydrofuran.

8. 6. The method of claim 5, wherein the solvent mixture is an ethanol:dichloromethane solvent mixture.

9. 9. The method of claim 8, wherein the solvent mixture is a solvent mixture of ethanol:dichloromethane (v / v) in the range of 5:1 to 1:

5.

10. 2. The method of claim 1, wherein step (A) of reducing the amide group of (R)-N-((R)-1-(naphthalen-1-yl)ethyl)chroman-2-carboxamide (Compound-5) using sodium bis(2-methoxyethoxy)aluminum hydride is carried out using a toluene solution of sodium bis(2-methoxyethoxy)aluminum hydride, followed by acid neutralization using concentrated hydrochloric acid.

Images